USE OF COMPOUNDS OF 1,3,4-THIADIAZINE CLASS AS AGENT FOR CORRECTION OF EXPERIMENTAL ALLOXAN DIABETES Russian patent published in 2016 - IPC A61K31/433 A61K31/5377 A61P3/10 

FIELD: medicine.

SUBSTANCE: invention relates to medicine, in particular to experimental pharmacology, novel biologically active compounds of general formula I, representing 2-morpholino-5-phenyl-6H-1,3,4-thiadiazin, hydrobromide (L-17); 2-morpholino-5-(4′-fluorophenyl)-6H-1,3,4-thiadiazin, hydrobromide (L-31), or general formula II: 2-amino propyl morpholino-5-phenyl-6H-1,3,4-thiadiazin, dihydrobromide (L-14); 2-amino propyl morpholino-5-(4′-fluorophenyl)-6H-1,3,4-thiadiazin, dihydrobromide (L-91) as agent for correction of experimental alloxan diabetes mellitus.

EFFECT: technical outcome is above compounds at intramuscular introduction in dosage of 40 mg/kg have antidiabetics action in development of alloxan diabetes in rats.

1 cl, 2 dwg, 1 tbl